Supernus Pharmaceuticals, Inc.
SUPN
$44.88
$1.563.60%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 290.23% | -177.16% | -60.18% | 93.30% | 15,961.29% |
| Total Depreciation and Amortization | 4.78% | 8.16% | -6.25% | -2.97% | -0.15% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -60.85% | -47.03% | 447.47% | 233.18% | -157.52% |
| Change in Net Operating Assets | -17.36% | 371.12% | 34.95% | -171.62% | -120.94% |
| Cash from Operations | 91.30% | -31.09% | -17.03% | 50.24% | -7.23% |
| Capital Expenditure | -39.14% | -53.52% | -6.50% | -212.50% | 74.19% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -180.10% | 402.97% | 83.82% | -58.28% | 5.54% |
| Cash from Investing | -182.02% | 395.28% | 83.59% | -58.48% | 5.87% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 60.43% | -70.31% | 98.64% | 108.68% | -42.99% |
| Repurchase of Common Stock | 98.62% | -238.50% | -155.04% | -38,600.00% | 99.93% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 88.58% | -- | -- | -- | -- |
| Cash from Financing | 104.37% | -463.31% | 91.54% | 85.46% | 5.61% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -37.95% | 23.52% | 284.45% | -80.48% | 2.93% |